Northland initiates coverage of ARS Pharmaceuticals with an outperform rating

nl.investing.com (Dutch)

Northland initiated coverage of ARS Pharmaceuticals with an outperform rating and a $25 price target, citing strong potential for its neffy product. The neffy intranasal epinephrine treatment aims to overcome barriers of injectable epinephrine. Northland projects over $1 billion in US peak sales, anticipating market access improvements. ARS Pharmaceuticals recently beat Q4 2025 earnings and revenue expectations. The FDA also updated neffy's label, removing an age restriction for certain weight ranges.


With a significance score of 1.2, this news ranks in the top 49% of today's 33283 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers:


Northland initiates coverage of ARS Pharmaceuticals with an outperform rating | News Minimalist